References
- Appel, S., Chapman, J., Shoenfeld, Y. (2007). Infection and vaccination in chronic fatigue syndrome: Myth or reality? Autoimmunity, 40, 48–53.
- Bansal, A. S., Bradley, A. S., Bishop, K. N., Kiani-Alikhan, S., Ford, B. (2012). Chronic fatigue syndrome, the immune system and viral infection. Brain Behav. Immun., 26, 24–31.10.1016/j.bbi.2011.06.016
- Barah, F., Vallely, P. J., Chiswick, M. L., Cleator, G. M., Kerr, J. R. (2001). Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet, 358, 729–730.
- Barah, F., Whiteside, S., Batista, S., Morris, J. (2014). Neurological aspects of human parvovirus B19 infection: A systematic review. Rev. Med. Virol., 24, 154–168.10.1002/rmv.1782
- Brenu, E. W., van Driel, M. L., Staines, D. R., Ashton, K. J., Ramos, S. B., Keane, J., Klimas, N. G., Marshall-Gradisnik, S. M. (2011). Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J. Transl. Med., 9, 81.10.1186/1479-5876-9-81
- Brown, K. E., Anderson, S. M., Young, N. S. (1993). Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science, 262, 114–117.
- Carruthers, B. M., van de Sande, M. I., De Meirleir, K. L., Klimas, N. G., Broderick, G., Mitchell, T., Staines, D., Powles, A. C., Speight, N., Vallings, R., Bateman, L., Baumgarten-Austrheim, B., Bell, D. S., Carlo-Stella, N., Chia, J., Darragh, A., Jo, D., Lewis, D., Light, A. R., Marshall-Gradisbik, S., Mena, I., Mikovits, J. A., Miwa, K., Murovska, M., Pall, M. L., Stevens, S. (2011). Myalgic encephalomyelitis: International Consensus Criteria. J. Intern. Med., 270, 327–338.
- Chapenko, S., Krumina, A., Kozireva, S., Nora, Z., Sultanova, A., Viksna, L., Murovska, M. (2006). Activation of human herpesviruses 6 and 7 in patients with chronic fatigue syndrome. J. Clin. Virol., 37 Suppl 1, S47–51.10.1016/S1386-6532(06)70011-7
- Chapenko, S., Krumina, A., Logina, I., Rasa, S., Chistjakovs, M., Sultanova, A., Viksna, L., Murovska, M. (2012). Association of active human herpesvirus-6, -7 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv. Virol., 2012, 205085.
- Cooling, L. L., Koerner, T. A., Naides, S. J. (1995). Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J. Infect. Dis., 172, 1198–1205.
- Corcoran, C., Hardie, D., Yeats, J., Smuts, H. (2010). Genetic variants of human parvovirus B19 in South Africa: Circulation of three genotypes and identification of a novel subtype of genotype 1. J. Clin. Microbiol., 48, 137–142.
- Cossart, Y. E., Field, A. M., Cant, B., Widdows, D. (1975). Parvovirus-like particles in human sera. Lancet, 1, 72–73.
- Couper, K. N., Blount, D. G., Riley, E. M. (2008). IL-10: The master regulator of immunity to infection. J. Immunol., 180, 5771–5777.
- Fremont, M., Metzger, K., Rady, H., Hulstaert, J., De Meirleir, K. (2009). Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. In Vivo, 23, 209–213.
- Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G., Komaroff, A. (1994). The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med., 121, 953–959.
- Guindon, S., Dufayard, J. F., Lefort, V., Anisimova, M., Hordijk, W., Gascuel, O. (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst. Biol., 59, 307–321.
- Hemauer, A., Gigler, A., Searle, K., Beckenlehner, K., Raab, U., Broliden, K., Wolf, H., Enders, G., Modrow, S. (2000). Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women. J. Med. Virol., 60, 48–55.10.1002/(SICI)1096-9071(200001)60:1<;48::AID-JMV9>3.0.CO;2-E
- Ito, K., Shimizu, N., Watanabe, K., Saito, T., Yoshioka, Y., Sakane, E., Tsunemine, H., Akasaka, H., Kodaka, T., Takahashi, T. (2013). Analysis of viral infection by multiplex polymerase chain reaction assays in patients with liver dysfunction. Intern. Med., 52, 201–211.2331884910.2169/internalmedicine.52.8206
- Johnston, S., Brenu, E. W., Staines, D., Marshall-Gradisnik, S. (2013). The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: A meta-analysis. Clin. Epidemiol., 5, 105–110.10.2147/CLEP.S3987623576883
- Kerr, J. R. (2000). Pathogenesis of human parvovirus B19 in rheumatic disease. Ann. Rheum. Dis., 59, 672–683.
- Kerr, J. R. (2016). The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J. Clin. Pathol., 69, 279–291.
- Kerr, J. R., Barah, F., Mattey, D. L., Laing, I., Hopkins, S. J., Hutchinson, I. V., Tyrrell, D. A. (2001). Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J. Gen. Virol., 82, 3011–3019.10.1099/0022-1317-82-12-3011
- Kerr, J. R., Gough, J., Richards, S. C., Main, J., Enlander, D., McCreary, M., Komaroff, A. L., Chia, J. K. (2010). Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J. Gen. Virol., 91, 893–897.10.1099/vir.0.017590-0
- Kerr, J. R., Tyrrell, D. A. (2003). Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr. Pain Headache Rep., 7, 333–341.10.1007/s11916-003-0031-3
- Luo, Y., Qiu, J. (2015). Human parvovirus B19: A mechanistic overview of infection and DNA replication. Future Virol., 10, 155–167.
- Magalhaes Ide, M., Martins, R. V., Vianna, R. O., Moyses, N., Afonso, L. A., Oliveira, S. A., Cavalcanti, S. M. (2011). Detection of human herpesvirus 7 infection in young children presenting with exanthema subitum. Mem. Inst. Oswaldo Cruz, 106, 371–373.
- Manaresi, E., Gallinella, G., Zerbini, M., Venturoli, S., Gentilomi, G., Musiani, M. (1999). IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J. Med. Virol., 57, 174–178.10.1002/(SICI)1096-9071(199902)57:2<;174::AID-JMV15>3.0.CO;2-0
- Matano, S., Kinoshita, H., Tanigawa, K., Terahata, S., Sugimoto, T. (2003). Acute parvovirus B19 infection mimicking chronic fatigue syndrome. Intern. Med., 42, 903–905.10.2169/internalmedicine.42.903
- Modrow, S., Dorsch, S. (2002). Antibody responses in parvovirus B19 infected patients. Pathol. Biol. (Paris), 50, 326–331.
- Momoeda, M., Wong, S., Kawase, M., Young, N. S., Kajigaya, S. (1994). A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity. J. Virol., 68, 8443–8446.
- Morey, A. L., Ferguson, D. J., Fleming, K. A. (1993). Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: Evidence of cell death by apoptosis. J. Pathol., 169, 213–220.
- Morinet, F., Corruble, E. (2012). Chronic fatigue syndrome and viral infections. In: Snell, C. R. (Ed.). An International Perspective on the Future of Research in Chronic Fatigue Syndrome. InTech, Croatia, pp. 1–12.
- Munakata, Y., Kato, I., Saito, T., Kodera, T., Ishii, K. K., Sasaki, T. (2006). Human parvovirus B19 infection of monocytic cell line U937 and antibody-dependent enhancement. Virology, 345, 251–257.
- Nicolson, G. L. (2002). Co-infections in fibromyalgia syndrome, chronic fatigue syndrome and other chronic illnesses. Fibromyalgia Frontiers,10, 5–9; 27–28.
- Ozawa, K., Ayub, J., Hao, Y. S., Kurtzman, G., Shimada, T., Young, N. (1987). Novel transcription map for the B19 (human) pathogenic parvovirus. J. Virol., 61, 2395–2406.
- Pfrepper, K. I., Enders, M., Motz, M. (2005). Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. J. Vet. Med. B Infect. Dis. Vet. Public Health, 52, 362–365.10.1111/j.1439-0450.2005.00874.x
- Sanders, P., Korf, J. (2008). Neuroaetiology of chronic fatigue syndrome: An overview. World J. Biol. Psychiatry, 9, 165–171.10.1080/15622970701310971
- Servant-Delmas, A., Lefrere, J. J., Morinet, F., Pillet, S. (2010). Advances in human B19 erythrovirus biology. J. Virol., 84, 9658–9665.10.1128/JVI.00684-10
- Soderlund-Venermo, M., Hokynar, K., Nieminen, J., Rautakorpi, H., Hedman, K. (2002). Persistence of human parvovirus B19 in human tissues. Pathol. Biol. (Paris), 50, 307–316.10.1016/S0369-8114(02)00307-3
- Soderlund, M., Brown, C. S., Spaan, W. J., Hedman, L., Hedman, K. (1995). Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J. Infect. Dis., 172, 1431–1436.
- Takahashi, Y., Murai, C., Shibata, S., Munakata, Y., Ishii, T., Ishii, K., Saitoh, T., Sawai, T., Sugamura, K., Sasaki, T. (1998). Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc. Natl. Acad. Sci. USA, 95, 8227–8232.
- Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S. (2013). MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol. Biol. Evol., 30, 2725–2729.
- von Poblotzki, A., Hemauer, A., Gigler, A., Puchhammer-Stockl, E., Heinz, F. X., Pont, J., Laczika, K., Wolf, H., Modrow, S. (1995). Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: Implications for pathogenesis. J. Infect. Dis., 172, 1356–1359.
- Zhang, L., Gough, J., Christmas, D., Mattey, D. L., Richards, S. C., Main, J., Enlander, D., Honeybourne, D., Ayres, J. G., Nutt, D. J., Kerr, J. R. (2010). Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J. Clin. Pathol., 63, 156–164.10.1136/jcp.2009.072561